Adalimumab biosimilar (Boehringer Ingelheim)

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameAdalimumab biosimilar (Boehringer Ingelheim)
Drug Alias NameAdalimumab-adbmCyltezoBI-695501
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPsoriasisUveitisCrohn Disease +[9] 
Global Approved IndicationsPsoriasisUveitisCrohn Disease +[9] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2017/08/25
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[28] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgQuallent Pharmaceuticals Health LLCGoodRx Inc +[4] 
Inactive CompaniesN/A
Active IndicationsPsoriasisCrohn DiseaseColitis, Ulcerative +[8] 
Inactive IndicationsUveitis

Other Information

ATC CodeL04AB04
Related LinksN/A